Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.